ReviewActa pharmaceutica Sinica. B2021
Biological drug and drug delivery-mediated immunotherapy.
Registry-linked trialOpen access · diamondAbstract readReview
In one paragraph
Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05379049 (Evaluation of the Therapeutic Response to TNF-alpha Antagonist), which is not on this map. Cited by 120 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Therapeutic Response to TNF-alpha Antagonist (Etanercept, Infliximab, Adalimumab) in Patients With Rheumatoid Arthritis; Using Plasma TNF-alpha as a Competent Biomarker. Single Center Study in Sulaymaniyah/ Iraq
Who cites it
120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 194 citations in OpenAlex.
- Effectiveness and safety of B cell-targeting biologics in the treatment of lupus nephritis: a systematic review and network meta‑analysis.Renal failure · 2024Pooled it
- Unlocking the secrets of NPSLE: the role of dendritic cell-secreted CCL2 in blood-brain barrier disruption.Frontiers in immunology · 2024Pooled it
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Trial
- [A prospective randomized controlled study on the curative effects of enteral immunonutrition support therapy in adult burn patients at nutritional risk].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022Trial
- Organization from cell to tissue derived delivery systems for immunotherapy.Materials today. Bio · 2026Article
- Injectable Hydrogels for Local Pharmacokinetic Control in Solid Tumors: From Passive Reservoirs to Stimulus-Responsive Exposure Systems.ACS pharmacology & translational science · 2026Review
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Inflammation and Immune Mechanisms in Atherosclerosis.Reviews in cardiovascular medicine · 2026Review
- Bioinspired and stimuli-responsive nanocomposites for targeted therapy in ovarian and endometrial tumors.International journal of pharmaceutics: X · 2026Review
- Application and prospects of nanomaterials in osteoporosis treatment.International journal of pharmaceutics: X · 2026Review
- Nanotechnology-mediated strategies for skeletal muscle repair and regeneration: targeted intervention, functional remodeling, and translational challenges.Journal of nanobiotechnology · 2026Review
- Biotransformation of Maclekarpine E in Rats: CYP2C19-Mediated Metabolism, Fecal Enrichment, and Network Pharmacology-Based Anti-Ulcerative Colitis Prediction.Current issues in molecular biology · 2026Article
- Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy.Acta pharmaceutica Sinica. B · 2026Review
- Remodeling the Inflammatory Microenvironment: Nanomaterial-Based Targeted Strategies for Systemic Lupus Erythematosus and Lupus Nephritis.Small science · 2026Review
- The relationship between CXC chemokines and cellular senescence: from mechanisms to therapy.Biogerontology · 2026Review
- Integrated bioinformatics and clinical validation reveals PRDX6 as a mitochondrial hub gene in systemic lupus erythematosus.Clinical rheumatology · 2026Article
- The role of macrophages in radiation-induced lung injury: from pathological mechanisms to therapeutic targets.Frontiers in immunology · 2026Review
- Recent Advancement in Drug Delivery Systems for the Treatment of Rheumatoid Arthritis.Current drug discovery technologies · 2026Review
- The plasticity and metabolic reprogramming of macrophage in ulcerative colitis.Frontiers in immunology · 2026Review
- Microbiota-Sensitive Nanocarriers for the Targeted Delivery of Therapeutic Agents into the Gut: Advanced Treatment Strategy for Inflammatory Bowel Disease.Current pharmaceutical design · 2026Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Qingqing XiaoSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Xiaotong LiSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Yi LiSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Zhenfeng WuKey Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China.
Chenjie XuDepartment of Biomedical Engineering, City University of Hong Kong, Hong Kong 999077, China.
Zhongjian ChenShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
Wei HeShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
China Pharmaceutical University · CNTongji University · CNCity University of Hong Kong · HKJiangxi University of Traditional Chinese Medicine · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
The initiation and development of major inflammatory diseases,
Indexed as
AAs, amino acidsACT, adoptive T cell therapyAdoptive cell transferAHC, Chlamydia pneumoniaALL, acute lymphoblastic leukemiaAP, ascorbyl palmitateAPCs, antigen-presenting cellsApoA–I, apolipoprotein A–IApoB LPs, apolipoprotein-B-containing lipoproteinsAS, atherosclerosisASIT, antigen-specific immunotherapyAtherosclerosisbDMARDs, biological DMARDsBiologicsBMPR-II, bone morphogenetic protein type II receptorBregs, regulatory B lymphocytesCancer immunotherapyCAR, chimeric antigen receptorCCR9–CCL25, CC receptor 9–CC chemokine ligand 25CD, Crohn's diseaseCETP, cholesterol ester transfer proteinCpG ODNs, CpG oligodeoxynucleotidesCTLA-4, cytotoxic T-lymphocyte-associated protein-4CX3CL1, CXXXC-chemokine ligand 1CXCL 16, CXC-chemokine ligand 16CXCR 2, CXC-chemokine receptor 2DAMPs, danger-associated molecular patternsDCs, dendritic cellsDDS, drug delivery systemDex, dexamethasoneDMARDs, disease-modifying antirheumatic drugsDMPC, 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholineDrug deliveryDSS, dextran sulfate sodiumECM, extracellular matrixECs, endothelial cellsEGFR, epidermal growth factor receptorEPR, enhanced permeability and retention effectET-1, endothelin-1ETAR, endothelin-1 receptor type AFAO, fatty acid oxidationGM-CSF, granulocyte–macrophage colony-stimulating factorHA, hyaluronic acidHDL, high density lipoproteinHER2, human epidermal growth factor-2hsCRP, high-sensitivity C-reactive proteinIBD, inflammatory bowel diseasesICOS, inducible co-stimulatorICP, immune checkpointIFN, interferonIL, interleukinImmune targetsInflammatory diseasesIT-hydrogel, inflammation-targeting hydrogelJAK, Janus kinaseLAG-3, lymphocyte-activation gene 3LDL, low density lipoproteinLPS, lipopolysaccharideLTB4, leukotriene B4mAbs, monoclonal antibodiesMCP-1, monocyte chemotactic protein-1MCT, monocrotalineMDSC, myeloid-derived suppressor cellMHCs, major histocompatibility complexesMHPC, 1-myristoyl-2-hydroxy-sn-glycero-phosphocholineMIF, migration inhibitory factorMM, multiple myelomaMMP, matrix metalloproteinaseMOF, metal–organic frameworkmPAP, mean pulmonary artery pressureMPO, myeloperoxidaseMSCs, mesenchymal stem cellsnCmP, nanocomposite microparticleNF-κB, nuclear factor κ-BNK, natural killerNPs, nanoparticlesNSAIDs, nonsteroidal anti-inflammatory drugsPAECs, pulmonary artery endothelial cellsPAH, pulmonary arterial hypertensionPASMCs, pulmonary arterial smooth muscle cellsPBMCs, peripheral blood mononuclear cellsPCSK9, proprotein convertase subtilisin kexin type 9PD-1, programmed death protein-1PD-L1, programmed cell death-ligand 1PLGA, poly lactic-co-glycolic acidPulmonary artery hypertensionRA, rheumatoid arthritisrHDL, recombinant HDLrhTNFRFc, recombinant human TNF-α receptor II-IgG Fc fusion proteinROS, reactive oxygen speciesscFv, single-chain variable fragmentSHP-2, Src homology 2 domain–containing tyrosine phosphatase 2SLE, systemic lupus erythematosusSMCs, smooth muscle cellsSrc, sarcoma geneTCR, T cell receptorTeff, effector T cellTGF-β, transforming growth factor βTh17, T helper 17TILs, tumor-infiltrating lymphocytesTIM-3, T-cell immunoglobulin mucin 3TLR, Toll-like receptorTNF, tumor necrosis factorTph, T peripheral helperTRAF6, tumor necrosis factor receptor-associated factor 6Tregs, regulatory T cellsUC, ulcerative colitisVEC, vascular endothelial cadherinVEGF, vascular endothelial growth factorVISTA, V-domain immunoglobulin-containing suppressor of T-cell activationYCs, yeast-derived microcapsulesα1D-AR, α1D-adrenergic receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT05379049ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.